Strides Pharma Science Ltd - 532531 - Stelis Biopharma - Q1 FY22 Investor Update
Please find attached Q1 FY22 Investor Update issued by Stelis Biopharma Ltd., the biopharmaceutical division of Strides.06-08-2021
06-08-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
The Board of Directors of the Company in their meeting held today have allotted 5,550 equity shares of face value of Rs. 10/- each to the eligible employees who have exercised their stock options under Strides ESOP 2016 Plan. These shares shall rank in pari passu with the existing equity shares of the Company in all respects. Consequent to above, the paid-up share capital of the Company has increased from Rs.89,71,71,640/- consisting of 8,97,17,164 equity shares of Rs. 10/- each to Rs.89,72,27,140/- consisting of 8,97,22,714 equity shares of Rs. 10/- each.06-08-2021
Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) For The Quarter Ended June 30, 2021
We are pleased to enclose the Unaudited Financial Results (Standalone and Consolidated) of the Company along with Limited Review Report of the Statutory Auditors for the quarter ended June 30, 2021, as approved by the Board of Directors of the Company at their meeting held today, along with a press release issued in this regard. The board meeting commenced at 10:15 hrs and concluded at 12:20 hrs. This is for your information and record.06-08-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides inks definitive agreement with Endo to acquire its manufacturing facility in the US along with basket of ANDAs06-08-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We write to inform that the Company shall host its earnings call with analysts and investors on Friday, August 6, 2021, at 03:30 pm IST to discuss the un-audited financial results of the Company for the quarter ended June 30, 2021. The dial-in details are attached for ready reference. Also kindly note, the transcript of the conference call will be posted on the Company's website at www.strides.com. This is for your kind information and record purpose.05-08-2021
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 SURIYA PRAKASH P04-08-2021
Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 ,inter alia, to consider and approve This is to inform you that meeting of Board of Directors of the Company is scheduled to be held on Friday, August 6, 2021 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2021, amongst other matters. Further, as per the provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for designated persons of the Company is closed from Thursday, July 1, 2021 upto Sunday, August 8, 2021 (both days inclusive). This is for your kind information and record purposes.29-07-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement titled 'Intimation about 30th Annual General Meeting of the Company & Record Date for Final Dividend'27-07-2021
Strides Pharma Science Ltd - 532531 - Intimation To Members About Annual General Meeting Of The Company And Record Date For The Purpose Of Final Dividend
We wish to inform you that 30th Annual General Meeting ('AGM') of the Company will be held over video conference/ other audio-visual means on Friday, September 3, 2021 at 12:30 hrs IST in compliance with the circulars issued by the Ministry of Corporate Affairs ('MCA'), Government of India and Securities and Exchange Board of India ('SEBI') and all other applicable laws. As informed by the Company on May 27, 2021, Board of Directors has recommended a final dividend of Rs. 2.50 per share. The Record Date for the purpose of Final Dividend for FY 2020-2021 will be Friday, August 6, 2021. Final Dividend once approved by the Members in the ensuing AGM will be paid within 30 days from the date of approval.26-07-2021
Strides Pharma Science Ltd - 532531 - Statement Of Investor Complaints For The Quarter Ended June 2021 (Revised)
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 133331 Name of the Signatory :- Manjula RamamurthyDesignation :- Company Secretary and Compliance Officer21-07-2021